Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: Prolonged or continuous infusion?

Pharmacotherapy

Volumn 27, Issue 11, 2007, Pages 1490-1497

  Kim, Aryun ^a   Sutherland, Christina A ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Continuous infusion; Monte Carlo simulation; Pharmacodynamics; Piperacillin tazobactam; Prolonged infusion; Pseudomonas aeruginosa

Indexed keywords

CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ARTICLE; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; SIMULATION;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 35848946597     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.11.1490     Document Type: Article

References (20)

1. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
2. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32: S146-55.
3. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
4. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320-32.
5. Lodise TP Jr, Lomaestro BM, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63.
6. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83.
7. Kuti JL, Grant EM, Sutherland CA, et al. Divergence in MIC distributions of Pseudomonas aeruginosa for piperacillin and piperacillin/tazobactam. J Infect Dis Pharmacotherapy 2001;5:41-51.
8. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44:51-7.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. CLSI document M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
10. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57:207-15.
11. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718-21.
12. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007;27: 333-42.
13. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-40.
14. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2003;23:916-24.
15. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007;58:337-44.
16. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36:S42-50.
17. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004;2:289-300.
18. Lau W, Mercer D, Itani K, et al. Randomized, open-label, comparative study of piperacillin/tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61.
19. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-95.
20. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.